Overview on Gynecologic Oncology

Dong-Ming Kuo, MD Department of Obstetrics and Gynecology Chang Gung Memorial Hospital

Gynaecological cancer : new cases and deaths per year in the UK

Site of malignancy

New cases per year Deaths per year

Ovary

Cervix

4400

5000

2200

4500

Endometrium 4400

1100

Lifetime Incidence of Cancer

• Breast

7.1%

• Ovary

1.4%

• Cervix

1.3%

• Endometrium

1.1%.

Five-year Survival Rates In Gynaecological Cancer

• Ovary

25%

• Cervix

55%

• Endometrium

66%.

Vulvar Cancer

- 5% of GYN malignancies
- Post menopausal, >65y/o, obese, hypertension,
 DM
- Most common primary site : labial major
- Dx : punch Bx, LN : fine needle aspiration
- Tx : <2cm, wide excision(>1cm clear margin)

LN (>1mm invasion)

>2cm,Radical vulvectomy(<1mm invasion) Radical vulvectomy+inguinal and femoral

• R/T : recurrence or nodal disease(LN>3 or pelvic LN+)

Vulval carcinoma : staging

Stage I Stage II Stage III Stage IVa Stage IVb

Tumour confined to vulva and <2 cm diameter. No nodes palpable Tumour confined to vulva but >2 cm diameter. No nodes palpable Tumour extends to lower urethra, vagina, or anus, or to unilateral inguinal nodes Tumour involves upper urethra, bladder, rectum, pelvic side wall, or bilateral inguinal nodes **Distant** spread

Vulval carcinoma : prognosis

Stage

5-year survival

70%

50%

32%

13%

IV

Improving The Outlook In Vulval Cancer Increased awareness of pruritus as a common presenting symptom Urgent biopsy of any suspicious lesion • Close follow-up of at-risk groups such as those with lichen sclerosus and VIN Excision of all tumour with at least 1 cm margin of normal tissue Less radical surgery for early disease. •

Vaginal Cancer

- Rare, 2% of GYN malignancies
- 2ndary spread from Cx Ca and EM Ca is more common
- Elderly women with PMB and discharge
- Most common site : upper post third, ulcer or polypoid
- Tx : R/T is preferred
- Survival : depends on stage

Pathology of Vaginal Cancer

- Squamous cell carcinoma
- Clear cell carcinoma
- Embryonal rhabdomyosarcoma (sarcoma botryoides)
- Malignant melanoma.

Vaginal cancer : staging • Stage I Tumour confined to vaginal wall Stage II Tumour involves subvaginal tissues, but not pelvic side wall Tumour extends to pelvic side Stage I wall Tumour involves bladder or Stage IV rectum, or has extended outside

the pelvis

Vaginal carcinoma : survival Stage **5-year survival** 70% III 45% 30% IV 10%

Cervical Cancer

- Usually over the age of 47.
- Etiology : HPV
- Screeing : Pap Smear
- Squamous carcinoma : 90%, Adenocarcinoma : most of the rest
- Direct invasion +LN meta, hematogenous spread is rare
- Symptoms occur when the tumor eroded into blood vessels or become infected
- Ia1: cone, ATH; Ia2: RAH+BPLD
- R/T : LN (+)
- Death result from uremia or cachexia

Risk Factors For Cancer Of The Cervix • Early age at first intercourse • Multiple sexual partners Sexually transmitted disease Smoking • Low socioeconomic status.

Cervical carcinoma : staging

Stage Features

- **0 Pre-invasive disease (CIN)**
- Ia Superficial invasive cervical carcinoma (microinvasion)
 Iai : up to 3 mm depth,< 7 mm wide
 Iaii : depth 3-5 mm, < 7 mm wide
 Ib Carcinoma confined to cervix
 Ibi < 4 cm in size
 Ibii > 4 cm in size
 IIa Carcinoma extends onto upper vagina
- **IIb** Carcinoma extends into parametrium, but does not reach pelvic side wall
- **IIIa** Carcinoma extends onto lower vagina
- **IIIb** Carcinoma extends to the pelvic side wall or cause Ureteric obstruction
- IVa Carcinoma involves bladder or rectum
- **IVb** Distant blood-borne spread

Invasive Cervical Cancer Treatment

Advantages of surgery

- Preservation of ovarian function
- Prognostic information from histology
- Easier to detect recurrent disease
- **Complications of surgery**
- Infection
- Bladder or ureteric injury
- Postoperative voiding problems
- Lymphocyst
- Thromboembolism

Advantages of radiotherapy

- Better tolerated by older women
- Major surgery avoided
- Useful in advanced disease
- **Complications of radiotherapy**
 - Vaginal stenosis
- Haematuria
- Dysuria
- Diarrhoea

carcinoma : 5-year survival by stage
5-year survival
80%
50%
30%
5%

Endometrial Cancer

- A disease of postmenopausal women (median : 60,rare below 40)
- Tend to present at an early stage with PMB • Better prognosis then Cx Ca and Ovarian Ca, but 25% die within 5 years of Dx Tx : Stage I : ATH+BSO+LN sampling , post OP R/T when poorly differentiated or penetrating the myometrium Advanced stage : post OP R/T Recurrent : palliative R/T, C/T

Malignant Tumours of The Uterus

Common

- Endometrial
 - carcinoma

Rare

- Leiomyosarcoma
- Endometrial stromal sarcoma
- Mixed mesodermal

tumour

Gestational trophoblastic
 disease

Risk Factors for Endometrial Carcinoma

- Obesity
- Nulliparity
- Late menopause
- Unopposed oestrogen stimulation
- Diabetes mellitus

Endometrial carcinoma : staging

Tumour confined to endometrium • Stage Ia Tumour invades myometrium, less than • Stage Ib 50% penetration Tumour invades myometrium, more than • Stage Ic 50% penetration Tumour involves the cervix • Stage II Spread to involve lymph nodes, uterine • Stage III serosa, adnexae or vagina Tumour involves bladder or rectum, or Stage IV Spread out of pelvis

Endometrial carcinoma : 5-year survival by stage

Stage

II

IV

5-year survival

75%

50% 30%

10%

Trophoblastic disease : classification

Benign

- Hydatidiform molePartial mole
- Malignant(gestational trophoblastic disease) • Invasive mole • Choriocarcinoma

Gestational Trophoblastic Neoplasia (GTN) • Benign hydatidiform moles, invasive mole, clioriocarcinoma • Tumor marker : β -hCG • Incidence : 1/1500-2000 pregnancies. • Increase in Asian women (Far East Asian > Asian Americans) • \downarrow folic acid and β -carotene

Molar Pregnancy

- PIH<24wks, hyperemesis, hyperthyroidism, 1st trimester bleeding
- Uterus>dates, theca-lutein cysts, snowstorm appearance β -hCG \uparrow , no fetus, CXR R/O lung meta
- Suction D&C+Sharp D&C
- Serial β-hCG follow-up +effective contraception for 1 year

Invasive Mole

• May enter the myometrium or uterus and cause hemorrhage

β-hCG titers tend to remain even after an evacuation

• Treat with hysterectomy

• Usually not associated with metastasis

Choriocarcinoma

- A malignant GTN
- Can display hematogenous spread to the lungs, vagina, brain, and GI tract
- Appears as : vaginal bleeding, hemoptysis (lung meta), dizziness (brain meta)and GI blecding (GI meta)
- C /T : MAC (Methotrexate, Actinomycin-D, Cyclophosphamide)
- Follow the β -hCG titers during treatment


Ovarian tumours : classification by tissue of origin

- **Pathological type**
 - Epithelial tumours
 - Sex cord tumours
 - Germ cell tumours
 - Metastatic tumours

Tissue of origin Surface epithelium of the ovary Sex cord cells of ovarian cortex Primordial germ cells Gastrointestinal or breast

Ovarian Cancer Epithelial in Origin 90%

- The most common cause of death from cancer of the genital tract .
- Peak at 60-70 years of age, Nulliparity, early menarche, late menopause .
- Oral pill offers protection .
- Familial and genetic origin : small percentage
- Death : cachexia 2ndary to chronic bowel dystunctim
- Dx : PV + sonar + Ca-125
 - Tx : Ia : USO or ATH+BSO, Ib,Ic : ATH+BSO+C/T or R/T Advanced : cytoreductive OP + C/T or R/T .



Site Pelvic Any peritoneal surfaces Pelvic and para-aortic lymph nodes Lung, liver

Ovarian cancer : staging

Stage IA Tumour confined to one ovary Stage IB Tumour involving both ovaries Tumour on one or both ovaries, with ascites Stage IC or positive peritoneal washings Stage II Tumour spread beyond the ovaries but confined to the pelvis Spread outside the pelvis but confined to Stage III the abdominal cavity Retroperitioneal spread to pelvic or paraaortic lymph nodes Stage IV **Distant** spread

Symptoms of Ovarian Cancer • Loss of appetite • Weight loss Indigestion Abdominal bloating • Pelvic discomfort • Vaginal bleeding.

The Role Of Surgery In Advanced Ovarian Cancer

- Diagnosis
- Staging
- Cytoreduction of tumour masses
- Drainage of ascites
- Relief of bowel or urinary obstruction
- Second look laparotomy / laparoscopy

Ovarian cancer : 5-year survival by stage **5-year survival** Stage 70% 40% 20% IV 5%

